Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
September 13, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE...
September 09, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

DEVON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
September 07, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

DEVON, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
September 02, 2021 07:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
September 02, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
August 09, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, in the third quarter of 2021Positive feedback from FDA clarifies potential path forward in ASDCash runway...
August 04, 2021 07:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference

DEVON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
July 07, 2021 07:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
June 30, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting

- 49% of shares voted, quorum not established to hold annual meeting – - Meeting scheduled to reconvene August 3, 2021 at 9:00 AM EDT – - Company strongly encourages stockholders holding unvoted...